Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
BMX Kinase
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "BMX Kinase" in MCE Product Catalog:
7
Target:
Research Areas:
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys 496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
3
3 Cited Publications
Synonyms: CHMFL-BMX 078
Target:
Research Areas:
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
2
2 Cited Publications
Synonyms: HM71224; LY3337641
Target:
Research Areas:
Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine kinase (BTK) inhibitor. With an IC50 of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis .
1
Target:
Research Areas:
Flixebrutinib (TL-895) is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor. Flixebrutinib is active against recombinant BTK (average IC50: 1.5 nM) and inhibits only three additional kinases BLK, BMX (IC50 = 1.6 nM) and TXK with IC50 within tenfold of BTK activity. Flixebrutinib inhibits BTK auto-phosphorylation at the Y223 phosphorylation site (IC50: 1-10 nM). The Flixebrutinib effectively inhibits the production of inflammatory factors such as IL-8, IL-1β, MCP-1 and TNF-α by monocytes or macrophages, and reduces the chemotactic migration of MF cells towards SDF-1. Flixebrutinib is used be for studies of chronic lymphocytic leukemia (CLL), myelofibrosis (MF), and B-cell malignancies .
Cat. No.: HY-174142
Target:
Research Areas:
IHMT-15130 is a highly potent irreversible BMX kinase inhibitor (IC50=1.47 nM). IHMT-15130 inhibits the secretion of inflammatory cytokines, blocks inflammatory signaling pathways, and alleviates Angiotensin II-induced myocardial hypertrophy in mice. IHMT-15130 is promising for research of myocardial hypertrophy .
Target:
Research Areas:
CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ～10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines .
Cat. No.: HY-117900
CAS No.: 1609465-89-5
Target:
Research Areas:
PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively .
Cat. No.: HY-117900A
CAS No.: 1609465-88-4
Target:
Research Areas:
(Rac)-PF-0625011 is a racemate of PF-06250112. PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor and shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC .
Cat. No.: HY-148594
CAS No.: 2573048-11-8
BTK-IN-23 is a BTK inhibitor (IC50: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC50s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997) .
Cat. No.: HY-187351
CAS No.: 3132799-96-0
Target:
Research Areas:
BMX-IN-4 is a covalent BMX kinase inhibitor with an IC50 of 1.78 nM and a Ki of 0.158 μM. BMX-IN-4 forms a covalent bond with BMX kinase. BMX-IN-4 is applicable to the research of hepatocellular carcinoma .
Cat. No.: HY-173280
CAS No.: 3035018-34-6
Synonyms: CHNQD-01228
Target:
Research Areas:
Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins. The IC50 value for the proliferation of T24 cells is 0.22 μM. It can also dose-dependently inhibit the migration and colony formation of T24 cells, induce G1 phase arrest and trigger Apoptosis. Brefeldin A 4-O-nicotinate exerts its anti-cancer activity by targeting the BMX protein to inhibit the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, as well as by inhibiting the Arf1 protein to eliminate bladder cancer stem cells and activate anti-tumor immunity. Brefeldin A 4-O-nicotinate can be used in the research related to bladder cancer .
Cat. No.: HY-173057
CAS No.: 2657662-64-9
Target:
Research Areas:
BMX-IN-3 (B6a) is an irreversible and selective BMX inhibitor, with an IC50 of 12 nM. BMX-IN-3 (B6a) promots cell cycle arrest and apoptosis, triggers protective autophagy, and suppresses the BMX/AKT/mTOR pathway. BMX-IN-3 (B6a) can be used in the research for Gastric Carcinoma .
Cat. No.: HY-101267R
CAS No.: 1808288-51-8
Synonyms: CHMFL-BMX 078 (Standard)
Target:
Research Areas:
CHMFL-BMX-078 (Standard) is the analytical standard of CHMFL-BMX-078 (HY-101267). This product is intended for research and analytical applications. CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
Research Areas:
Protein kinase inhibitor 6 is a protein kinase inhibitor.
Cat. No.: HY-P701711
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BMX; Cytoplasmic Tyrosine-Protein Kinase BMX; BMX Non-Receptor Tyrosine Kinase; BTK-Like On X Chromosome; ETK; Etk/BMX Cytosolic Tyrosine Kinase; PSCTK3; NTK38 Tyrosine Kinase; Bone Marrow Tyrosine Kinase Gene In Chromosome X Protein; PSCTK2; Epithelial A
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P701712
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BMX; Cytoplasmic Tyrosine-Protein Kinase BMX; BMX Non-Receptor Tyrosine Kinase; BTK-Like On X Chromosome; ETK; Etk/BMX Cytosolic Tyrosine Kinase; PSCTK3; NTK38 Tyrosine Kinase; Bone Marrow Tyrosine Kinase Gene In Chromosome X Protein; PSCTK2; Epithelial A
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P706020
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: BMX; Cytoplasmic Tyrosine-Protein Kinase BMX; BMX Non-Receptor Tyrosine Kinase; BTK-Like On X Chromosome; ETK; Etk/BMX Cytosolic Tyrosine Kinase; PSCTK3; NTK38 Tyrosine Kinase; Bone Marrow Tyrosine Kinase Gene In Chromosome X Protein; PSCTK2; Epithelial A
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-182902
Target:
Research Areas:
IHMT-15137 is a BMX inhibitor with an IC50 of 26.97 nM. IHMT-15137 covalently binds to BMX Cys496 within the ATP-binding pocket, inhibits BMX phosphorylation at Tyr566, and disrupts the BMX-ERK1/2-Cyclin D1/CDK4/6-E2F1 signaling axis. IHMT-15137 reduces E2F1 protein stability via decreased Ser332/337 phosphorylation, increased ubiquitination, and ubiquitin-proteasome pathway degradation. IHMT-15137 induces cell cycle arrest, apoptosis, DNA damage, and suppresses cell migration and invasion. IHMT-15137 can be used for the research of small cell lung cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
